Yttrium-90 ibritumomab tiuxetan
Publisher
Radiopaedia.org
Reference7 articles.
1. Hagenbeek A, Bischof-Delaloye A, Radford J et al. 90Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma: First Results of the International Randomized Phase 3 First-Line Indolent Trial (FIT) in 414 Patients. Blood. 2007;110(11):643.
2. Morschhauser F, Radford J, Van Hoof A et al.
3. Rizzieri D. Zevalin(®) (Ibritumomab Tiuxetan): After More Than a Decade of Treatment Experience, What Have We Learned? Crit Rev Oncol Hematol. 2016;105:5-17.
4. Wright C, Zhang J, Tweedle M, Knopp M, Hall N. Theranostic Imaging of Yttrium-90. BioMed Research International. 2015;2015:1-11.
5. Witzig T, Molina A, Gordon L et al. Long-Term Responses in Patients with Recurring or Refractory B-Cell Non-Hodgkin Lymphoma Treated with Yttrium 90 Ibritumomab Tiuxetan. Cancer. 2007;109(9):1804-10.